Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2003-8-15
pubmed:abstractText
Nuclear factor-kappaB (NF-kappaB) plays a central role in myocardial ischemia-reperfusion (MI/R) injury. The inhibitory protein IkappaBalpha prevents its activation. We investigated the effects of adeno-associated viral vector-mediated IkappaBalpha gene transfer in MI/R injury. Male C57BL/6 mice were randomized to receive a recombinant adeno-associated virus (rAAV) encoding the gene for the NF-kappaB inhibitory protein IkappaBalpha (rAAV- IkappaBalpha) or the beta-galactosidase gene (a control and inert gene; rAAV-LacZ), both at a dose of 10(11) copies. Four weeks later anesthetized animals were subjected to total occlusion (45 minutes) of the left main coronary artery followed by 5 hours of reperfusion. MI/R produced a wide infarct size (IF/area-at-risk = 56 +/- 8%; IF/left ventricle = 44 +/- 5%) and tissue neutrophil infiltration, studied by means of elastase activity (area-at-risk = 2.5 +/- 0.4 micro g/gm tissue; infarct area = 2.9 +/- 0.6 micro g/gm tissue). Furthermore MI/R caused peak message for intercellular adhesion molecule-1 (ICAM-1) in the area-at-risk at 3 hours of reperfusion (1.2 +/- 0.4 relative amount of cardiac ICAM-1 mRNA). NF-kappaB activation was evident at 0.5 hours of reperfusion and reached its maximum increase at 2 hours of reperfusion. rAAV-IkappaBalpha injection reduced infarct size (IF/area-at-risk = 19 +/- 3%; IF/left ventricle = 10 +/- 2%; p < 0.001), blocked NF-kappaB activation, diminished cardiac ICAM-1 expression (0.4 +/- 0.02 relative amount of cardiac ICAM-1 mRNA; p < 0.001), and blunted leukocyte accumulation (area-at-risk = 0.6 +/- 0.05 micro g/gm tissue; infarct area = 0.4 +/- 0.02 micro g/gm tissue; p < 0.001). Our data indicate that rAAV-IkappaBalpha may be useful for MI/R gene therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0023-6837
pubmed:author
pubmed:issnType
Print
pubmed:volume
83
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1097-104
pubmed:dateRevised
2005-11-17
pubmed:meshHeading
pubmed-meshheading:12920239-Adenoviridae, pubmed-meshheading:12920239-Animals, pubmed-meshheading:12920239-Blotting, Western, pubmed-meshheading:12920239-DNA Primers, pubmed-meshheading:12920239-Gene Therapy, pubmed-meshheading:12920239-Gene Transfer Techniques, pubmed-meshheading:12920239-Heart Ventricles, pubmed-meshheading:12920239-I-kappa B Proteins, pubmed-meshheading:12920239-Intercellular Adhesion Molecule-1, pubmed-meshheading:12920239-Male, pubmed-meshheading:12920239-Mice, pubmed-meshheading:12920239-Mice, Inbred C57BL, pubmed-meshheading:12920239-Myocardial Infarction, pubmed-meshheading:12920239-Myocardial Reperfusion Injury, pubmed-meshheading:12920239-NF-kappa B, pubmed-meshheading:12920239-Pancreatic Elastase, pubmed-meshheading:12920239-RNA, Messenger, pubmed-meshheading:12920239-Transduction, Genetic, pubmed-meshheading:12920239-beta-Galactosidase
pubmed:year
2003
pubmed:articleTitle
Gene transfer of IkappaBalpha limits infarct size in a mouse model of myocardial ischemia-reperfusion injury.
pubmed:affiliation
Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy. Francesco.Squadrito@unime.it
pubmed:publicationType
Journal Article